Volume 12, Issue 1 (10-2024)
Jorjani Biomed J 2024, 12(1): 14-17 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mahdianipur S, Mohammadi S, Jaefari A, Davoodi H. Effect of phenelzine and serotonin on RAW264.7 macrophage cell viability. Jorjani Biomed J 2024; 12 (1) :14-17
URL: http://goums.ac.ir/jorjanijournal/article-1-1023-en.html
URL: http://goums.ac.ir/jorjanijournal/article-1-1023-en.html
1- Immunology Department, Medicine Faculty, Golestan University of Medical Sciences, Gorgan, Iran
2- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
3- Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran ,jafari_a67@yahoo.com
4- Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2- Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
3- Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran ,
4- Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Abstract: (955 Views)
Background: Serotonin is a neurotransmitter with extensive physiological effects on the Central Nervous System (CNS) and various biological functions, including the regulation of immunity through 5-hydroxytryptamine receptors (5-HTRs) expressed by immune cells such as macrophages. Phenelzine, a medication used in managing treatment-resistant depression, acts as a potent monoamine oxidase inhibitor (MAOI). This enzyme metabolizes serotonin into 5-hydroxyindoleacetic acid (5-HIAA). Antidepressants e.g., Phenelzine may benefit patients with neurological disorders, who can also be prone to immune-related conditions and cancer. This study aimed to investigate the cytotoxic effects of Phenelzine, serotonin, and 5-HIAA on RAW264.7 macrophages.
Methods: We cultured RAW264.7 macrophages as a model that could express transporter receptors and enzymes associated with serotonin. We utilized MTT assay to evaluate the survival of RAW264.7 cells exposed to different concentrations of Phenelzine, serotonin, and 5-HIAA, pre-treated with lipopolysaccharide (LPS).
Results: Our findings revealed that LPS-treated RAW264.7 cells exhibited increased resistance to the cytotoxic effects of Phenelzine. Treatment with serotonin resulted in a concentration-dependent increase in RAW264.7 cell proliferation. In contrast, 5-HIAA did not significantly impact cell viability.
Conclusion: The present study reveals the effect of Phenelzine and serotonin on viability of RAW264.7 macrophages, particularly in the context of inflammation. It demonstrates increased resistance to the cytotoxic effects of Phenelzine in RAW264.7 cells treated with LPS. Our study contributes to a broader understanding of the potential systemic impacts of antidepressant medications and the intricate interplay between the serotonergic system and immune responses.
Methods: We cultured RAW264.7 macrophages as a model that could express transporter receptors and enzymes associated with serotonin. We utilized MTT assay to evaluate the survival of RAW264.7 cells exposed to different concentrations of Phenelzine, serotonin, and 5-HIAA, pre-treated with lipopolysaccharide (LPS).
Results: Our findings revealed that LPS-treated RAW264.7 cells exhibited increased resistance to the cytotoxic effects of Phenelzine. Treatment with serotonin resulted in a concentration-dependent increase in RAW264.7 cell proliferation. In contrast, 5-HIAA did not significantly impact cell viability.
Conclusion: The present study reveals the effect of Phenelzine and serotonin on viability of RAW264.7 macrophages, particularly in the context of inflammation. It demonstrates increased resistance to the cytotoxic effects of Phenelzine in RAW264.7 cells treated with LPS. Our study contributes to a broader understanding of the potential systemic impacts of antidepressant medications and the intricate interplay between the serotonergic system and immune responses.
Type of Article: Original article |
Subject:
Basic Medical Sciences
Received: 2024/01/2 | Accepted: 2024/02/3 | Published: 2024/02/27
Received: 2024/01/2 | Accepted: 2024/02/3 | Published: 2024/02/27
References
1. Gershon MD. Serotonin: its role and receptors in enteric neurotransmission. Adv Exp Med Biol. 1991;294:221-30. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Chase TN, Murphy DL. Serotonin and central nervous system function. Annu Rev Pharmacol. 1973;13:181-97. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Yadav VK, Oury F, Suda N, Liu Z-W, Gao X-B, Confavreux C, et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell. 2009;138(5):976-89. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Gershon MD, Drakontides AB, Ross LL. Serotonin: Synthesis and release from the myenteric plexus of the mouse intestine. Science. 1965;149(3680):197-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Costedio MM, Hyman N, Mawe GM. Serotonin and its role in colonic function and in gastrointestinal disorders. Dis Colon Rectum. 2007;50(3):376-88. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132(1):397-414. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Wan M, Ding L, Wang D, Han J, Gao P. Serotonin: A Potent Immune Cell Modulator in Autoimmune Diseases. Front Immunol. 2020;11:186. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Herr N, Bode C, Duerschmied D. The Effects of Serotonin in Immune Cells. Front Cardiovasc Med. 2017;4:48. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Mössner R, Lesch KP. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun. 1998;12(4):249-71. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Casas-Engel M, Domínguez-Soto A, Sierra-Filardi E, Bragado R, Nieto C, Puig-Kroger A, et al. Serotonin skews human macrophage polarization through HTR2B and HTR7. J Immunol. 2013;190(5):2301-10. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Wu H, Denna TH, Storkersen JN, Gerriets VA. Beyond a neurotransmitter: The role of serotonin in inflammation and immunity. Pharmacol Res. 2019;140:100-14. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Battaglino R, Fu J, Späte U, Ersoy U, Joe M, Sedaghat L, et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res. 2004;19(9):1420-31. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Ito M, Haito S, Furumoto M, Kawai Y, Terao J, Miyamoto K. Approach to novel functional foods for stress control 4. Regulation of serotonin transporter by food factors. J Med Invest. 2005;52 Suppl:245-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Gross ME, Agus DB, Dorff TB, Pinski JK, Quinn DI, Castellanos O, et al. Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(1):61-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Culpepper L. Reducing the Burden of Difficult-to-Treat Major Depressive Disorder: Revisiting Monoamine Oxidase Inhibitor Therapy. Prim Care Companion CNS Disord. 2013;15(5):PCC.13r01515. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Rapaport MH. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art. J Clin Psychiatry. 2007;68(Suppl 8):42-6. [View at Publisher] [PMID] [Google Scholar]
17. Thase ME. MAOIs and depression treatment guidelines. J Clin Psychiatry. 2012;73(7):e24. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Molinoff PB, Axelrod J. Biochemistry of catecholamines. Annu Rev Biochem. 1971;40:465-500. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Cathcart MK, Bhattacharjee A. Monoamine oxidase A (MAO-A): a signature marker of alternatively activated monocytes/macrophages. Inflamm Cell Signal. 2014;1(4):e161. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Entzeroth M, Ratty AK. Monoamine Oxidase Inhibitors-Revisiting a Therapeutic Principle. Open Journal of Depression. 2017;6(02):31-68. [View at Publisher] [DOI] [Google Scholar]
21. Saunders JC, Roukema RW, Kline NS, D'a Baily S. Clinical results with phenelzine. Am J Psychiatry. 1959;116(1):71-2. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Furst W. Therapeutic re-orientation in some depressive states: clinical evaluation of a new mono-amine oxidase inhibitor (W-1554-A, phenelzine, Nardil). Am J Psychiatry. 1959;116(5):429-34. [View at Publisher] [DOI] [PMID] [Google Scholar]
23. Smith KA, Fairburn CG, Cowen PJ. Relapse of depression after rapid depletion of tryptophan. Lancet. 1997;349(9056):915-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
24. Berman RM, Narasimhan M, Miller HL, Anand A, Cappiello A, Oren DA, et al. Transient Depressive Relapse Induced by Catecholamine Depletion: Potential Phenotypic Vulnerability Marker? Arch Gen Psychiatry. 1999;56(5):395-403. [View at Publisher] [DOI] [PMID] [Google Scholar]
25. Ruhé HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry. 2007;12(4):331-59. [View at Publisher] [DOI] [PMID] [Google Scholar]
26. Anderson IM, Parry-Billings M, Newsholme EA, Poortmans JR, Cowen PJ. Decreased plasma tryptophan concentration in major depression: relationship to melancholia and weight loss. J Affect Disord. 1990;20(3):185-91. [View at Publisher] [DOI] [PMID] [Google Scholar]
27. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 2005;10(6):538-44. [View at Publisher] [DOI] [PMID] [Google Scholar]
28. Cowen PJ, Browning M. What has serotonin to do with depression? World Psychiatry. 2015;14(2):158-60. [View at Publisher] [DOI] [PMID] [Google Scholar]
29. Masson J, Emerit MB, Hamon M, Darmon M. Serotonergic signaling: multiple effectors and pleiotropic effects. Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. 2012;1(6):685-713. [View at Publisher] [DOI] [Google Scholar]
30. El Oussini H, Bayer H, Scekic-Zahirovic J, Vercruysse P, Sinniger J, Dirrig-Grosch S, et al. Serotonin 2B receptor slows disease progression and prevents degeneration of spinal cord mononuclear phagocytes in amyotrophic lateral sclerosis. Acta Neuropathol. 2016;131(3):465-80. [View at Publisher] [DOI] [PMID] [Google Scholar]
31. Sangaran PG, Ibrahim ZA, Chik Z, Mohamed Z, Ahmadiani A. Lipopolysaccharide Pre-conditioning Attenuates Pro-inflammatory Responses and Promotes Cytoprotective Effect in Differentiated PC12 Cell Lines via Pre-activation of Toll-Like Receptor-4 Signaling Pathway Leading to the Inhibition of Caspase-3/Nuclear Factor-κappa B Pathway. Front Cell Neurosci. 2020;14:598453. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
